
This episode discusses the Phase 3 trial of Atacicept for the treatment of IgA Nephropathy with insights from experts in renal medicine.
The Filtrate Joel Topf @kidneyboy.bsky.social ( COI ) Sophia Ambruso @sophia-kidney.bsky.social Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn Special Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies) Editing and Show Notes by Nayan Arora @captainchloride.bsky.social The Kidney Connection written and performed by Tim Yau Show Notes Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed ) The number, quality, and coverage of randomized controlled trials in nephrology ( PubMed 2004 ) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction ( PubMed 2017) BLISS Be limumab in lupus nephritis ( Neph JC | P ubMed ) The Phase 2 trial of atacicept A phase 2b, randomized, double -blind, pl acebo-controlled, clinical trial of at acicep t for trea tment of IgA nephropathy ( PubMed ) The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephr opathy (Pu bMed | NephJC ) The use of Gd-Ig A1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and…
Explore listener stats, chart rankings, contacts and more on the Freely Filtered, a NephJC Podcast podcast page.